Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
Amir Mehrvarz Sarshekeh(The University of Texas MD Anderson Cancer Center), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Raja Luthra(The University of Texas MD Anderson Cancer Center), Cathy Eng(Vanderbilt University), Keyur P. Patel(The University of Texas MD Anderson Cancer Center), Arvind Dasari(The University of Texas MD Anderson Cancer Center), Imad Shureiqi(University of Michigan), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Mark J. Routbort(The University of Texas MD Anderson Cancer Center), Eduardo Vilar(The University of Texas MD Anderson Cancer Center), Bryan K. Kee(The University of Texas MD Anderson Cancer Center), Dipen M. Maru(The University of Texas MD Anderson Cancer Center), Kenna Shaw(Center for Personalized Cancer Treatment), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Shailesh Advani(The University of Texas MD Anderson Cancer Center), Michael J. Overman(The University of Texas MD Anderson Cancer Center), Shanequa Manuel(The University of Texas MD Anderson Cancer Center), David R. Fogelman(The University of Texas MD Anderson Cancer Center)
Cited by 88
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k